April 30 (Reuters) - WellPoint Inc said on Wednesday during a conference call that it had spent $50 million on hepatitis C drugs during the first quarter.
That was the total amount the company spent in 2013 on treatments, it said. Gilead Sciences introduced Sovaldi this year, and with its $84,000 price tag and high cure rates, it has been closely watched by insurers tracking expenses.
WellPoint added $100 million in additional hepatitis C drug costs to its 2014 outlook and said it continued to watch its use closely. (Reporting by Caroline Humer; Editing by Lisa Von Ahn)